In recent years, immune cell markers such as CD8+, CD163+, PD-L1+, and FOXP3 have shown prognostic impacts in patients suffering from solid tumors including NSCLC (9, 10, 20). Here, FOXP3 is linked to non-small cell lung carcinoma.